drugset / Trial / NCT01050751

Bioavailability Of Lersivirine Single 750 Mg Tablet Versus 3 X 250 Mg Tablets

NCT01050751

Phase 1 Completed 12 enrolled Pfizer
RandomizedCrossoverOpen-labelTreatment

Summary

This is a randomized study to assess whether the pharmacokinetics of a new single 750 mg tablet is similar to 3 x 250 mg tablets (750 mg total).

Timeline

Start
2010-02
Primary completion
2010-03
Completion
2010-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Lersivirine Small molecule 750 mg Oral

Indications

No indication recorded.